Entrada Therapeutics reported financial results for the quarter ended June 30, 2026. The company held $223.0 million in cash and marketable securities as of June 30, sufficient to fund operations into Q3 2027. Collaboration revenue was $0.9 million, while R&D expenses were $35.4 million and G&A expenses were $10.5 million, resulting in a net loss of $42.8 million. Clinically, ELEVATE-44-201 Cohort 2 enrollment is complete with data expected in Q1 2027, while ELEVATE-45-201 Cohort 2 dosing is ongoing at an increased dose of 10 mg/kg. The company plans to report ELEVATE-45-201 Cohort 1 data in October 2026 and ELEVATE-44-201 Cohort 1 open-label data by year-end 2026. Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines for neuromuscular diseases.

At its 2026 Annual Meeting held on June 10, 2026, Entrada Therapeutics, Inc. stockholders elected Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. to the Board of Directors as Class II directors. Shareholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Additionally, the meeting resulted in the approval of Amendment No. 1 to the 2021 Stock Option and Incentive Plan and Amendment No. 1 to the 2021 Employee Stock Purchase Plan, both of which modify evergreen provisions to include outstanding pre-funded warrants in the share count calculations. Entrada Therapeutics, Inc. is a biotechnology company focused on therapeutic development.